Abbott: tightens up target ranges for 2024

(CercleFinance.com) - Abbott Laboratories has tightened up its target ranges for adjusted EPS and organic sales growth (excluding Covid-19 test revenues), to $4.
55-4.70 and 8.5%-10% respectively, for the current year.

For Q1 2024, it reports adjusted EPS of $0.98, down 4.9% y-o-y, despite revenues increasing 2.2% to $9.96bn, which it says is athanks to the solid performance of underlying core businesses.

On an organic basis and excluding sales linked to Covid-19 tests, the healthcare group's quarterly sales rose by 10.8%, representing its fifth consecutive quarter of double-digit growth.


Copyright (c) 2024 CercleFinance.com. All rights reserved.